The fair values of the assets acquired in business combinations, including goodwill, are set out in the table below.
| Novartis | ||||||||||||
| Consumer | Novartis | |||||||||||
| Healthcare | Vaccines | |||||||||||
| business | business | Other | ||||||||||
| £m | £m | £m | ||||||||||
|
Net assets acquired: |
||||||||||||
|
Intangible assets |
6,003 | 2,680 | 124 | |||||||||
|
Property, plant and equipment |
249 | 434 | 1 | |||||||||
|
Inventory |
257 | 347 | — | |||||||||
|
Trade and other receivables |
400 | 162 | 2 | |||||||||
|
Other assets including cash and cash equivalents |
304 | 283 | 19 | |||||||||
|
Trade and other payables |
(402 | ) | (107 | ) | (3 | ) | ||||||
|
Deferred tax liabilities |
(1,154 | ) | (78 | ) | (26 | ) | ||||||
|
Other liabilities |
(165 | ) | (299 | ) | — | |||||||
|
|
|
|
|
|
|
|||||||
| 5,492 | 3,422 | 117 | ||||||||||
|
Non-controlling interest |
(2,150 | ) | (19 | ) | — | |||||||
|
Goodwill |
774 | 576 | 22 | |||||||||
|
|
|
|
|
|
|
|||||||
| 4,116 | 3,979 | 139 | ||||||||||
|
|
|
|
|
|
|
|||||||
|
Consideration settled by shares in GSK Consumer Healthcare Holdings |
4,116 | — | — | |||||||||
|
Cash consideration paid after purchase adjustments |
— | 3,461 | 124 | |||||||||
|
Fair value of equity investment disposal |
— | — | 15 | |||||||||
|
Contingent consideration |
— | 594 | — | |||||||||
|
Deferred tax on contingent consideration |
— | (52 | ) | — | ||||||||
|
Loss on settlement of pre-existing relationships |
— | (24 | ) | — | ||||||||
|
|
|
|
|
|
|
|||||||
|
Total consideration |
4,116 | 3,979 | 139 | |||||||||
|
|
|
|
|
|
|
|||||||